All In Biotech

Drug Trial Radar · NCT06927739

Focused Orticumab Research for Treating Inflammation in Coronary Arteries

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Orticumab in Participants With Prior Myocardial Infarction Who Have Elevated Coronary Inflammation Based on FAI Score Assessed by CCTA

Last checked: Nov 19, 2026Latest source record: Jan 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Aug 11, 2025

Primary completion

Feb 8, 2027

Study completion Jun 1, 2027

Sponsor

Lead sponsor
AbcentraIndustry
Sponsor type
Industry
First posted
Apr 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to determine the clinical effect of orticumab treatment on inflammation in study participants with prior myocardial infarction who have elevated coronary inflammation based on CCTA. The main question it aims to answer is: Clinical effects of orticumab treatment on inflammation of the coronary artery parameters measured with CCTA Researchers will compare the effects with placebo group after 6 months of treatment Participants will Keep the planned study visit appointments Provide complete information about medical and medical history Speak to the study doctor before changing any of non-study treatments, including starting new medications, receiving any vaccinations, or setting out to join any other clinical studies

Conditions

  • Acute Coronary Syndromes
  • Coronary Arterial Disease (CAD)
  • Inflammation
  • Heart Disease
  • Myocardial Infarct
  • Atherosclerotic Coronary Vascular Disease

Interventions

  • OrticumabDrug

    Orticumab treatment for 24 weeks for post MI population

  • PlaceboDrug

    Placebo for 24 weeks for the post MI population

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change from baseline of the mean Fat Attenuation Index (FAI) score for the 3 coronary arteries (RCA, LAD and LCX) for orticumab compared to placebo at 24 weeksTime frame: 24 weeks

Locations

41 sites in 9 countries. Site status is shown where the registry gives one.

  • Abcentra Investigational Site

    Los Angeles, California · Not yet recruiting

  • Abcentra Investigational Site

    Torrance, California · Recruiting

  • Abcentra Investigational Site

    Boca Raton, Florida · Recruiting

  • Abcentra Investigational Site

    Richmond, Indiana · Recruiting

  • Abcentra Investigational Site

    Louisville, Kentucky · Not yet recruiting

  • Abcentra Investigational Site

    Baltimore, Maryland · Recruiting

  • Abcentra Investigational Site

    Midland, Michigan · Recruiting

  • Abcentra Investigational Site

    Ostrava, Moravian-Silesian Region, Czechia · Recruiting

  • Abcentra Investigational Site

    Pilsen, Plzeň Region, Czechia · Recruiting

  • Abcentra Investigational Site

    Prague, Praha 2, Czechia · Recruiting

  • Abcentra Investigational Site

    Prague, Praha 4, Czechia · Recruiting

  • Abcentra Investigational Site

    Brno, South Moravian, Czechia · Recruiting

  • Abcentra Investigational Site

    Pécs, Baranya, Hungary · Recruiting

  • Abcentra Investigational Site

    Budapest, Central Hungary, Hungary · Recruiting

  • Abcentra Investigational Site

    Budapest, Central Hungary, Hungary · Recruiting

  • Abcentra Investigational Site

    Budapest, Central Hungary, Hungary · Recruiting

  • Abcentra Investigational Site

    Nyíregyháza, Szabolcs-Szatmár-Bereg, Hungary · Recruiting

  • Abcentra Investigational Site

    Caserta, Campania, Italy · Recruiting

  • Abcentra Investigational Site

    Ferrara, Ferrara, Italy · Recruiting

  • Abcentra Investigational Site

    Brescia, Lombardy, Italy · Recruiting

  • Abcentra Investigational Site

    Milan, Lombardy, Italy · Recruiting

  • Abcentra Investigational Site

    Pavia, Lombardy, Italy · Recruiting

  • Abcentra Investigational Site

    Krakow, Lesser Poland Voivodeship, Poland · Recruiting

  • Abcentra Investigational Site

    Wroclaw, Lower Silesian Voivodeship, Poland · Recruiting

  • Abcentra Investigational Site

    Warsaw, Masovian Voivodeship, Poland · Recruiting

  • Abcentra Investigational Site

    Baia Mare, Maramureş, Romania · Recruiting

  • Abcentra Investigational Site

    Târgu Mureş, Mureș County, Romania · Recruiting

  • Abcentra Investigational Site

    Timișoara, Timiș County, Romania · Recruiting

  • Abcentra Investigational Site

    Córdoba, Andalusia, Spain · Recruiting

  • Abcentra Investigational Site

    Madrid, Madrid, Spain · Recruiting

  • Abcentra Investigational Site

    Madrid, Madrid, Spain · Recruiting

  • Abcentra Investigational Site

    El Palmar, Murcia, Spain · Recruiting

  • Abcentra Investigational Site

    Seville, Sevilla, Spain · Recruiting

  • Abcentra Investigational Site

    Danderyd, Stockholm County, Sweden · Recruiting

  • Abcentra Investigational Site

    Solna, Stockholm County, Sweden · Recruiting

  • Abcentra Investigational Site

    Gothenburg, Västra Götaland County, Sweden · Recruiting

  • Abcentra Investigational Site

    London, Greater London, United Kingdom · Recruiting

  • Abcentra Investigational Site

    Manchester, Greater Manchester, United Kingdom · Recruiting

  • Abcentra Investigational Site

    Oxford, Oxfordshire, United Kingdom · Recruiting

  • Abcentra Investigational Site

    Bath, Somerset, United Kingdom · Recruiting

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.